<DOC>
	<DOCNO>NCT01531452</DOCNO>
	<brief_summary>The purpose study determine efficacy safety oxaliplatin s1 first-line treatment advance gastric cancer .</brief_summary>
	<brief_title>The Efficacy Oxaliplatin Plus S-1 Treatment Gastric Cancer</brief_title>
	<detailed_description>There evidence standard chemotherapy advance gastric cancer ( AGC ) China . Fluoropyrimidines cisplatin widely use variety combination treatment AGC . Capecitabine/cisplatin combination therapy show overall response rate ( ORR ) 41- 55 % , median time progression/progression free survival ( TTP/PFS ) 5.6-6.3 month , median overall survival ( OS ) 10.1-10.5 month . Though study compare two oral fluoropyrimidines combination oxaliplatin , S-1 capecitabine appear comparable term efficacy safety . The investigator conduct phase II trial oxaliplatin combine S-1 treatment first-line AGC .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven operable advanced gastric adenocarcinoma ( include adenocarcinoma gastrooesophageal junction ) relapse gastric adenocarcinoma Measurable lesion and/or nonmeasurable lesion define RECIST ECOG performance status ≦ 1 Hgb ≧ 8g/dL , WBC 400012000/mm3 , platelet ≧ 100,000/mm3 Creatine ≦ upper normal limit ( UNL ) Total bilirubin ≦ 1.5 X UNL AST , ALT ALP ≦ 2.5 x UNL Subjects must able take orally No prior chemotherapy Life expectancy estimate 3 month Written inform consent Pregnancy lactation woman , woman suspect pregnancy men willing get pregnant Known brain metastasis History hypersensitivity fluoropyrimidines , oxaliplatin Active double cancer Treatment investigational product last 4 week prior study entry Symptomatic peripheral neuropathy ≧ garde 2. NCICTCAE ver.3.0 Any previous chemotherapy radiotherapy AGC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>drug therapy</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>s1</keyword>
</DOC>